As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.
17 Analysts have issued a 89bio Inc forecast:
17 Analysts have issued a 89bio Inc forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -405 -405 |
125%
125%
|
EBIT (Operating Income) EBIT | -405 -405 |
125%
125%
|
Net Profit | -387 -387 |
134%
134%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.
Head office | United States |
CEO | Rohan Palekar |
Employees | 93 |
Founded | 2018 |
Website | www.89bio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.